Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
11
Active, not recruiting, industry sponsors, Hematology and blood cancers, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed194
11 trials
Showing 1 to 11, recently updated first.
- A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple MyelomaActive, not recruiting
Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
NCT07030517 · 75 participants · Start May 22, 2025 · Primary completion Feb 12, 2027
Drug: Teclistamab · For: Multiple Myeloma
Sites: Bangalore, India; Bengaluru, India; Chandigarh, India · 12 sites in all
- A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab ProphylaxisActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05181618 · 136 participants · Start Jun 20, 2022 · Primary completion Nov 19, 2026
Drug: Emicizumab · For: Severe Hemophilia A; Moderate Hemophilia A
Sites: Miami, Florida; Oklahoma City, Oklahoma; Campinas, Brazil · 26 sites in all
- CINC424A2X01B Rollover ProtocolActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT02386800 · 279 participants · Start Mar 5, 2015 · Primary completion Apr 5, 2032
Drug: ruxolitinib; panobinostat · For: Primary Myelofibrosis; Polycythemia Vera; Graft Versus Host Disease and 2 more
Sites: Darlinghurst, Australia; Herston, Australia; Wooloongabba, Australia · 97 sites in all
- Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving TopotecanPivotal-lookingActive, not recruiting
Pharmacosmos A/SIndustry
NCT05874401 · 302 participants (planned) · Start Oct 13, 2023 · Primary completion Feb 5, 2028
Drug: Trilaciclib; Placebo and 1 more · For: Extensive-stage Small-cell Lung Cancer
Sites: Seville, Spain
- Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaActive, not recruiting
Swedish Orphan BiovitrumIndustry
NCT06940830 · 252 participants · Start May 21, 2025 · Primary completion Dec 2028
Drug: Efanesoctocog alfa · For: Hemophilia A
Sites: Zagreb, Croatia; Brno, Czechia; Ostrava, Czechia · 31 sites in all
- Lorlatinib Continuation StudyActive, not recruiting
PfizerPfizer (PFE)
NCT05144997 · 76 participants · Start Dec 28, 2021 · Primary completion Oct 25, 2029
Drug: Lorlatinib · For: Non-Small-Cell Lung Cancer; NSCLC
Sites: Irvine, California; Hefei, China; Beijing, China · 27 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05891249 · 85 participants (planned) · Start Jun 5, 2023 · Primary completion Dec 16, 2028
Drug: Luspatercept · For: Anemia
Sites: Ahmedabad, India; New Delhi, India; Kolkata, India · 9 sites in all
- A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa ProphylaxisActive, not recruiting
Swedish Orphan BiovitrumIndustry
NCT06752850 · 37 participants · Start Dec 19, 2024 · Primary completion Nov 17, 2026
Drug: Efanesoctocog alfa · For: Haemophilia A (Moderate or Severe); Hemophilia, Classic; Haemophilia and 3 more
Sites: Milan, Italy; Naples, Italy; Rozzano, Italy · 10 sites in all
- Crizotinib Continuation Clinical StudyActive, not recruiting
PfizerPfizer (PFE)
NCT05160922 · 27 participants · Start Dec 27, 2021 · Primary completion Mar 21, 2028
Drug: crizotinib · For: NSCLC; ALCL; IMT
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 13 sites in all
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Active, not recruiting
Pharmacyclics Switzerland GmbHAbbVie (ABBV)
NCT03229200 · 297 participants · Start May 22, 2017 · Primary completion May 10, 2027
Drug: Ibrutinib · For: Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, B-cell and 2 more
Sites: Burbank, California; Duarte, California; La Jolla, California · 98 sites in all
AbbVieAbbVie (ABBV)
NCT05144243 · 44 participants · Start Jan 6, 2022 · Primary completion Mar 2026
Drug: Venetoclax; Azacitidine · For: Acute Myeloid Leukemia (AML)
Sites: Beijing, China; Guangzhou, China; Shenzhen, China · 18 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.